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Abstract
Objective To investigate the efficacy and safety of ocrelizumab in patients with
class III/IV lupus nephritis (LN). Methods Patients were randomized 1:1:1 to
receive placebo, 400 mg ocrelizumab, or 1,000 mg ocrelizumab given as an
intravenous infusion on days 1 and 15, followed by a single infusion at week 16
and every 16 weeks thereafter, accompanied by background glucocorticoids plus
either mycophenolate mofetil (MMF) or the Euro-Lupus Nephritis Trial (ELNT)
regimen (cyclophosphamide followed by azathioprine). The study was terminated
early due to an imbalance in serious infections in ocrelizumab-treated patients
versus placebo-treated patients. We report week 48 efficacy data for patients
receiving ≥32 weeks of treatment (n = 223) and safety results for all treated
patients (n = 378). Results The overall renal response rate was 54.7%, 66.7%,
67.1%, and 66.9% in the placebo-treated, 400 mg ocrelizumab-treated, 1,000 mg
ocrelizumab-treated, and combined ocrelizumab-treated groups,...
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Efficacy and Safety of Ocrelizumab in
Active Proliferative Lupus Nephritis
Results From a Randomized, Double-Blind, Phase III Study
Eduardo F. Mysler,1 Alberto J. Spindler,2 Renato Guzman,3 Marc Bijl,4
David Jayne,5 Richard A. Furie,6 Fre´de´ric A. Houssiau,7 Jorn Drappa,8 David Close,9
Romeo Maciuca,8 Kajal Rao,10 Saba Shahdad,† and Paul Brunetta8
Objective. To investigate the efficacy and safety of
ocrelizumab in patients with class III/IV lupus nephritis
(LN).
Methods. Patients were randomized 1:1:1 to re-
ceive placebo, 400 mg ocrelizumab, or 1,000 mg ocreli-
zumab given as an intravenous infusion on days 1 and
15, followed by a single infusion at week 16 and every
16 weeks thereafter, accompanied by background gluco-
corticoids plus either mycophenolate mofetil (MMF) or
the Euro-Lupus Nephritis Trial (ELNT) regimen (cyclo-
phosphamide followed by azathioprine). The study was
terminated early due to an imbalance in serious infec-
tions in ocrelizumab-treated patients versus placebo-
treated patients. We report week 48 efficacy data for
patients receiving >32 weeks of treatment (n  223)
and safety results for all treated patients (n  378).
Results. The overall renal response rate was
54.7%, 66.7%, 67.1%, and 66.9% in the placebo-treated,
400 mg ocrelizumab–treated, 1,000 mg ocrelizumab–
treated, and combined ocrelizumab-treated groups, re-
spectively. The associated treatment difference versus
placebo for the combined ocrelizumab-treated groups
was 12.7% (95% confidence interval [95% CI] 0.8,
26.1) (P  0.065), with similar differences observed for
both ocrelizumab-treated groups. Ocrelizumab versus
placebo treatment differences were apparent in patients
receiving the background ELNT regimen, but not in
those receiving background MMF. A numerically
greater proportion of ocrelizumab-treated patients
had a >50% reduction in the urinary protein:urinary
creatinine ratio at 48 weeks compared with placebo-
treated patients (placebo-treated patients, 58.7%;
400 mg ocrelizumab–treated patients, 70.7%; 1,000 mg
ocrelizumab–treated patients, 68.5%). Serious adverse
events occurred in 27.2% of placebo-treated patients,
35.7% of 400 mg ocrelizumab–treated patients, and
22.0% of 1,000 mg ocrelizumab–treated patients. Corre-
sponding serious infection rates (events/100 patient-
years) were 18.7 (95% CI 12.2, 28.7), 28.8 (95% CI 20.6,
40.3), and 25.1 (95% CI 17.4, 36.1), respectively. The
imbalance in serious infections with ocrelizumab oc-
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curred with background MMF but not with the back-
ground ELNT regimen.
Conclusion. In patients with active LN, overall
renal response rates with ocrelizumab were numerically
but not statistically significantly superior to those with
placebo. Ocrelizumab treatment was associated with a
higher rate of serious infections in the subgroup receiv-
ing background MMF.
Approximately 60% of patients with systemic
lupus erythematosus (SLE) develop renal involvement
(lupus nephritis [LN]), and LN remains an important
contributor to the increased morbidity and mortality
associated with SLE (1). The standard treatment for LN
is guided by histologic classification according to Inter-
national Society of Nephrology/Renal Pathology Society
criteria (2), with treatment of patients with class III/IV
LN usually involving a short period of intense induction
therapy followed by a prolonged period of maintenance
treatment (3). Based on the results of several robust
clinical trials (4–10), recent guidelines published by
the American College of Rheumatology (ACR) (11) and
the European League Against Rheumatism/European
Renal Association–European Dialysis and Transplant
Association (12) recommend mycophenolate mofetil
(MMF) or cyclophosphamide (CYC) for induction of
improvement in patients with International Society of
Nephrology class III/IV lupus glomerulonephritis (11).
B cells are strongly implicated in the patho-
genesis of SLE and LN (13–17). Belimumab, a mono-
clonal antibody that neutralizes the B cell survival factor
B lymphocyte stimulator, recently received Food and
Drug Administration approval for the treatment of
SLE (18). In addition, rituximab, a chimeric anti-CD20
monoclonal antibody, has shown encouraging results in
several studies (19–21). Recently, rituximab was evalu-
ated in a large, international, randomized, placebo-
controlled trial (Lupus Nephritis Assessment of Ritux-
imab [LUNAR]) in patients with class III or class IV LN
(22). In the LUNAR trial, there were numerically more
responders in the rituximab-treated group, but the 11%
difference versus placebo was not statistically signifi-
cant (patients with complete or partial renal response at
week 52: rituximab-treated 56.9%, placebo-treated
45.8%; P  0.18).
Ocrelizumab (2H7) is a recombinant humanized
monoclonal antibody that also selectively targets and
depletes CD20 B cells in the peripheral circulation.
Ocrelizumab possesses enhanced antibody-dependent
cell-mediated cytotoxicity and reduced complement-
dependent cytotoxicity compared with rituximab in vitro
(data on file; Genentech) and was originally investigated
in a phase II study in patients with rheumatoid arthritis
(RA) (23). A comprehensive phase III program further
evaluated ocrelizumab in RA. Two pivotal trials tested
ocrelizumab at 2 dose levels (2  200 mg and 2  500
mg, with the doses given 2 weeks apart) in combination
with methotrexate (MTX) (24,25). Both doses improved
the signs and symptoms of RA and also significantly
reduced progressive joint damage in the STAGE study,
a randomized, double-blind, parallel-group international
study to evaluate the safety and efficacy of ocrelizumab
compared with placebo in patients with active RA
continuing MTX treatment (25). Although the overall
incidence of adverse events (AEs) and infections was
similar between ocrelizumab and placebo in both trials,
a higher rate of serious infections was observed with the
higher dose compared with placebo in the STAGE study
(25) and with both doses in the SCRIPT study, a
randomized, double-blind, parallel-group international
study to evaluate the safety and efficacy of ocrelizumab
compared with placebo in patients with active RA who
have had an inadequate response to at least 1 anti–
tumor necrosis factor therapy (24).
The current, BELONG study, a study to evaluate
ocrelizumab in patients with nephritis due to SLE, was
conducted to determine the efficacy and safety of ocreli-
zumab compared with placebo in patients with active LN
who were also receiving glucocorticoids plus standard of
care of CYC (Euro-Lupus Nephritis Trial [ELNT] reg-
imen) or MMF. An imbalance in the rate of serious and
opportunistic infections in ocrelizumab-treated patients,
together with the results from the rituximab LUNAR
study (22), led the sponsor to reassess the benefit/risk
ratio of anti-CD20 therapy in patients with LN and to
terminate the BELONG study early. As a result, this
report includes safety data for all treated patients and
week 48 efficacy data for patients who had received
treatment within the study for at least 32 weeks.
PATIENTS AND METHODS
Patients. Patients were age 16 years and had SLE
according to the ACR 1982 revised criteria (26), including a
history of antinuclear antibody positivity and active LN (de-
fined as a urinary protein:urinary creatinine ratio 1 with
biopsy-proven [within 6 months prior to randomization] World
Health Organization [WHO] [2] or International Society of
Nephrology class III or IV LN [excluding III (C), IV-S (C), and
IV-G (C)], with coexisting class V permitted; or WHO class III
or IV glomerulonephritis, provided that 50% of glomeruli
showed sclerosis or fibrosis). Key exclusion criteria were active
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retinitis, poorly controlled seizure disorder, acute confusional
state, myelitis, stroke or stroke syndrome, cerebellar ataxia or
dementia, severe renal impairment, estimated glomerular fil-
tration rate 25 ml/minute per 1.73 m2 of body surface area,
end-stage renal disease requiring dialysis or transplant, throm-
bocytopenia, or experiencing or at high risk of developing
clinically significant bleeding or organ dysfunction.
Study design. This was a multicenter, randomized,
double-blind, placebo-controlled, parallel-group, phase III study
(Figure 1). The initial double-blind, placebo-controlled period
lasted 48 weeks. Patients with an adequate clinical response at
48 weeks continued blinded treatment through week 96, while
those with an inadequate clinical response could receive
open-label treatment. Safety followup started when a patient
discontinued from any of the treatment periods for any reason,
and patients remained in safety followup for at least 48 weeks
following the last infusion of study drug.
Patients were randomized 1:1:1 to receive placebo,
400 mg ocrelizumab, or 1,000 mg ocrelizumab given as an intra-
venous (IV) infusion on days 1 and 15, followed by a single
infusion at week 16 and every 16 weeks thereafter. All patients
received MMF (target dose 3 gm/day) or CYC (ELNT regi-
men: 500 mg IV every 2 weeks 6). The choice of background
induction therapy regimen was at the discretion of the inves-
tigator. Patients receiving MMF continued to receive MMF,
while patients receiving the ELNT CYC regimen were sub-
sequently treated with azathioprine (AZA; 2 mg/kg up to
200 mg/day, dose selected by the investigator). IV steroids (up
to 3 gm/day) were also permitted by day 15, given in divided
pulses, and oral steroids (0.5–0.75 mg/kg [60 mg/day]) were
allowed with taper to 10 mg over 10 weeks. Before each
infusion, patients were administered IV methylprednisolone
(100 mg), acetaminophen/paracetamol (1 gm), and an anti-
histamine (50 mg IV diphenhydramine HCl or equivalent).
The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki or with the laws and
regulations of the country in which the research was con-
ducted, and all patients provided written informed consent.
Efficacy assessments. Clinical response was assessed in
the following 3 mutually exclusive categories at week 48:
complete renal response (normal serum creatinine [25%
increase from baseline] and improvement in urinary protein:
urinary creatinine ratio to0.5), partial renal response (serum
creatinine 25% above baseline, and 50% improvement in
urinary protein:urinary creatinine ratio, and if baseline ratio
3.0, then urinary protein:urinary creatinine ratio 3.0), and
nonresponse (no complete or partial renal response). Death or
discontinuation from the study prior to week 48 (and no renal
data available within 12 weeks of week 48) was considered a
nonresponse.
Safety assessments. AEs were recorded throughout
the study and graded according to the National Cancer In-
stitute Common Terminology Criteria for Adverse Events,
version 3.
Statistical analysis. Based on an estimated complete
renal response rate of 40% in the ocrelizumab-treated group
and 30% in the placebo-treated group, a partial renal response
rate of 40% in the ocrelizumab-treated group and 25% in the
placebo-treated group, and a nonresponse rate of 20% in the
ocrelizumab-treated group and 45% in the placebo-treated
group, and allowing for a 15% dropout rate, 369 patients (123
per treatment arm) were required to detect a difference with
80% power between active and control treatment arms at a
2-sided alpha level of 0.025.
The analysis population for efficacy outcomes con-
sisted of a subset of randomized patients treated for 32
weeks prior to study termination, and who had a baseline
urinary protein:urinary creatinine ratio 1 (a few treated
Figure 1. Study design. SOC  standard of care.
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patients did not meet this entry criterion). This population
(modified intent-to-treat [ITT] population) was defined after
the decision to stop dosing. The cutoff of 32 weeks was used
because it included patients who had the opportunity to
receive at least 4 double-blind infusions of study drug with
outcomes least biased by the decision to stop the study.
The primary end point was the proportion of patients
with a renal response (complete renal response, partial renal
response, or nonresponse) at week 48. Renal responses in the
3 categories were summarized descriptively; the difference in
overall renal response (complete renal response or partial
renal response) at week 48 was analyzed using the Cochran-
Mantel-Haenszel test, adjusting for race and standard of care.
The safety population comprised all patients who
received at least 1 infusion of ocrelizumab or placebo. Safety
data up to week 48 are presented descriptively.
RESULTS
Patient population. At the time of study termi-
nation (October 19, 2009), 381 patients from 123 sites in
23 countries had been randomized to study treatment
(the ITT population). Three patients who were random-
ized (1 from each study group) did not receive treat-
ment, 1 due to an AE, 1 for administrative reasons, and
1 due to withdrawal of consent. The remaining 378
patients received at least 1 infusion of ocrelizumab or
placebo (the safety population). Due to the early study
termination, only 139 patients (36.8%) completed the
48-week, double-blind treatment period. The reasons for
withdrawal are shown in Table 1. The modified ITT
population for efficacy analysis consisted of 223 patients
(75, 75, and 73 patients in the placebo-treated, 400 mg
ocrelizumab–treated, and 1,000 mg ocrelizumab–treated
groups, respectively).
This was the first trial outside Europe to enroll
patients in an ELNT regimen. Patients were included
from sites in Latin America (42%), Asia (23.1%), West-
ern Europe (12.9%), Eastern Europe (10.5%), the US
and Canada (10.2%), and Africa (1.3%). Overall, 63%
of patients received MMF and 37% received the ELNT
regimen. Use of the ELNT regimen ranged from 68% in
Eastern Europe to 18% in the US and Canada. Patients
reached the target MMF dose of 3 gm/day in 3 weeks,
and MMF was not tapered before week 48.
Baseline demographic characteristics were well
balanced, although the 1,000 mg ocrelizumab–treated
group had a slightly higher proportion of white patients
and a lower proportion of Asian patients than did the
other 2 groups (Table 2). In general, there were no
notable differences between the groups in the frequency
of concomitant medication use during the treatment
period, except for a somewhat lower proportion of
patients in the 1,000 mg ocrelizumab–treated group who
used statins and angiotensin II receptor antagonists
(data not shown). All patients received IV glucocortico-
ids at baseline (during screening or on day 1). The
cumulative IV glucocorticoid dose received during
screening/day 1 was similar between treatment groups
(overall median dose 500 mg [range 100–3,100 mg]).
However, the IV glucocorticoid dose received on day 1
was lower for patients receiving the ELNT regimen than
for patients receiving MMF (median 100 mg versus
500 mg).
Efficacy. The overall renal response rate at 48
weeks was 54.7%, 66.7%, and 67.1% in the placebo-
treated, 400 mg ocrelizumab–treated, and 1,000 mg
ocrelizumab–treated groups, respectively (Table 3). The
overall renal response rate for the 2 ocrelizumab-treated
groups combined was 66.9%. The associated treatment
differences (versus placebo) were 12.1% (95% confi-









Discontinued prior to week 48 80 (64.0) 79 (62.7) 80 (63.0)
Adverse event/intercurrent illness 3 (2.4) 6 (4.8) 3 (2.4)
Death 3 (2.4) 0 4 (3.1)
Insufficient therapeutic response 1 (0.8) 2 (1.6) 0
Failure to return 0 1 (0.8) 1 (0.8)
Violation of selection criteria at entry 1 (0.8) 0 1 (0.8)
Other protocol violation 1 (0.8) 0 2 (1.6)
Refused treatment/did not cooperate 0 1 (0.8) 1 (0.8)
Withdrew consent 3 (2.4) 4 (3.2) 1 (0.8)
Administrative/other† 68 (54.4) 65 (51.6) 67 (52.8)
* Values are the number (%) of patients.
† The vast majority of withdrawals in this category were due to the early termination of the study.
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dence interval [95% CI] 3.3, 27.5), 13.9% (95% CI
1.4, 29.2), and 12.7% (95% CI 0.8, 26.1) for the
400 mg ocrelizumab–treated, 1,000 mg ocrelizumab–
treated, and the 2 ocrelizumab-treated groups com-
bined, respectively. A numerically greater proportion of
ocrelizumab-treated patients had a 50% reduction in
the urinary protein:urinary creatinine ratio at 48 weeks
compared with placebo-treated patients (placebo-
treated patients, 58.7%; 400 mg ocrelizumab–treated
patients, 70.7%; 1,000 mg ocrelizumab–treated patients,
68.5%). The proportion of patients with a urinary pro-
tein:urinary creatinine ratio 0.5 at 48 weeks was
37.3%, 44.0%, and 35.5% in the placebo-treated, 400 mg
ocrelizumab–treated, and 1,000 mg ocrelizumab–treated
groups, respectively.
Week 48 renal response by standard of care regi-
men. When stratified by background standard of care,
there was a trend (P  0.065) toward greater overall
renal response rates at 48 weeks with ocrelizumab
treatment and the ELNT regimen versus placebo treat-
ment and the ELNT regimen (Table 3). Adjusted treat-
ment differences (versus placebo) were 31.3% (95% CI
7.4, 55.3) and 14.7% (95% CI –10.0, 39.6) for the 400 mg
ocrelizumab–treated and 1,000 mg ocrelizumab–treated
groups, respectively. Higher observed overall renal re-
sponse rates and complete renal response rates in the











Female, no. (%) 107 (84.9) 115 (90.6) 110 (85.9) 332 (87.1)
Age
Mean (range) years 31.3 (17–66) 31.9 (16–69) 30.6 (16–60) 31.3 (16–69)
30 years, % 51 47 53 50
Race, no. (%)
White 58 (46.0) 55 (43.3) 67 (52.3) 180 (47.2)
Asian 35 (27.8) 39 (30.7) 27 (21.1) 101 (26.5)
American Indian/Native Alaskan 17 (13.5) 17 (13.4) 15 (11.7) 49 (12.9)
Black 5 (4.0) 7 (5.5) 7 (5.5) 19 (5.0)
Other 11 (8.7) 9 (7.1) 12 (9.4) 32 (8.4)
Ethnicity, no. (%)
Hispanic 51 (40.5) 58 (45.7) 58 (45.3) 167 (43.8)
Non-Hispanic 75 (59.5) 69 (54.3) 70 (54.7) 214 (56.2)
LN class, no. (%)
III 30 (23.8) 23 (18.1) 25 (19.5) 78 (20.5)
IV 96 (76.2) 104 (81.9) 103 (80.5) 303 (79.5)
V with III/IV 23 (18.3) 21 (16.5) 25 (19.5) 69 (18.1)
Time from biopsy to randomization, median
(range) days
32 (4–168) 27.5 (2–134) 32 (5–195) 31 (2–195)
SLE duration, median (range) years 3.9 (0–20) 3.9 (0–20) 3.9 (0–25) 3.9 (0–25)
LN duration, median (range) years 0.6 (0–19) 0.8 (0–20) 0.7 (0–20) 0.7 (0–20)
Patients receiving background MMF 0.9 (0–19) 1.5 (0–16) 1.2 (0–20) 1.1 (0–20)
Patients receiving background ELNT regimen 0.3 (0–15) 0.4 (0–20) 0.4 (0–19) 0.3 (0–20)
Asian patients 4.4 (0–14) 1.4 (0–11) 3.2 (0–20) 2.1 (0–20)
Non-Asian patients 0.4 (0–19) 0.8 (0–19) 0.6 (0–18) 0.6 (0–19)
Urinary protein:urinary creatinine ratio
(24 hours), median (% with median 3)
2.7 (46) 3.0 (50) 2.9 (50) 2.8 (49)
Patients receiving background MMF 2.5 (45) 2.6 (46) 2.8 (46) 2.6 (46)
Patients receiving background ELNT regimen 2.9 (48) 3.6 (58) 4.1 (56) 3.3 (54)
Asian patients 2.9 (50) 3.8 (66) 3.6 (57) 3.5 (58)
Non-Asian patients 2.6 (45) 2.5 (45) 2.8 (49) 2.6 (46)
Serum creatinine, mean SD mg/dl
Patients receiving background MMF 0.9  0.4 1.0  0.6 1.0 0.5 0.9  0.5
Patients receiving background ELNT regimen 0.9 0.4 1.1  0.8 1.0 0.5 1.0  0.6
Asian patients 0.8  0.4 1.0  0.5 1.0 0.5 0.9  0.5
Non-Asian patients 0.9 0.4 1.0  0.7 1.0 0.5 1.0  0.6
C3, mean  SD mg/dl 65 26 71  47 69 31 68  36
C4, mean  SD mg/dl 15  9 15 7 15  7 15  7
Anti-dsDNA, geometric mean IU/ml 121 100 117 112
* LN lupus nephritis; SLE systemic lupus erythematosus; MMFmycophenolate mofetil; ELNT Euro-Lupus Nephritis Trial; anti-dsDNA
anti–double-stranded DNA.
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400 mg ocrelizumab–treated group with the ELNT
regimen were consistent over time (see Supplementary
Figure 1, available on the Arthritis & Rheumatism web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.
38037/abstract). Most patients receiving the ELNT reg-
imen (82%) in the modified ITT population received at
least 6 doses of 500 mg IV CYC up to week 16, with a
similar frequency in all treatment groups.
Adding ocrelizumab to background MMF had
little effect on the overall renal response rate, with
adjusted treatment differences (versus MMF alone) of
0.3% (95% CI 20.0, 19.7) and 13.3% (95% CI 6.0,
32.6) for the 400 mg ocrelizumab–treated and 1,000 mg
ocrelizumab–treated groups, respectively (Table 3). In
the modified ITT population, the daily dose of MMF
over the 48 weeks of treatment was comparable among
the treatment groups, with mean  SD doses of 2.2 
0.6, 2.0  0.6, and 2.1  0.7 gm/day for the placebo-
treated, 400 mg ocrelizumab–treated, and 1,000 mg
ocrelizumab–treated groups, respectively.
There were no apparent meaningful differences
between treatment groups with respect to mean daily
oral prednisone dose over the 48-week study period,
both overall and within each standard of care subgroup.
The mean  SD daily dose in the modified ITT popu-
lation over 48 weeks was 14  6 mg (median 12 mg).
After week 12, the mean and median prednisone dose
was 10 mg.
In the modified ITT population, approximately
one-third of patients received a baseline IV glucocorti-
coid dose of500 mg, one-third received 500–1,000 mg,
and the remaining one-third received 1,000 mg.
The proportion of patients receiving baseline IV gluco-
corticoid doses 1,000 mg was higher in the MMF
group (46%, versus 22% for the ELNT regimen), with
a greater difference among placebo-treated patients
















CRR, no. (%) 26 (34.7) 32 (42.7) 23 (31.5) 55 (37.2)
PRR, no. (%) 15 (20.0) 18 (24.0) 26 (35.6) 44 (29.7)
ORR, no. (%) 41 (54.7) 50 (66.7) 49 (67.1) 99 (66.9)
95% CI for the ORR, % 43.4, 65.9 56.0, 77.3 56.3, 77.9 59.3, 74.5
Adjusted treatment difference, %
(95% CI)†
– 12.1 (3.3, 27.5) 13.9 (1.4, 29.2) 12.7 (0.8, 26.1)
P‡ – – – 0.065
ELNT regimen§
CRR, no. (%) 7 (25) 14 (45) 8 (24) 22 (34)
PRR, no. (%) 5 (18) 9 (29) 11 (33) 20 (31)
ORR, no. (%) 12 (43) 23 (74) 19 (58) 42 (66)
95% CI for the ORR, % 24.5, 61.2 58.8, 89.6 40.7, 74.4 54.0, 77.3
Adjusted treatment difference, %
(95% CI)†
– 31.3 (7.4, 55.3) 14.7 (10.0, 39.6) 22.8 (1.1, 44.5)
P‡ – – – 0.065
MMF§
CRR, no. (%) 19 (40) 18 (41) 15 (38) 33 (39)
PRR, no. (%) 10 (21) 9 (20) 15 (38) 24 (29)
ORR, no. (%) 29 (62) 27 (61) 30 (75) 57 (68)
95% CI for the ORR, % 47.8, 75.6 47.0, 75.8 61.6, 88.4 57.9, 77.8
Adjusted treatment difference, %
(95% CI)†
– 0.3 (20.0, 19.7) 13.3 (6.0, 32.6) 6.2 (11, 23.3)
P‡ – – – 0.57
* CRR  complete renal response; PRR  partial renal response; ORR  overall renal response (complete renal response combined with partial
renal response); 95% CI  95% confidence interval (see Table 2 for other definitions).
† Stratified by standard of care regimen and compared with placebo.
‡ Versus placebo, by Cochran-Mantel-Haenszel test.
§ Among patients receiving the background ELNT regimen, 28 were receiving placebo, 31 were receiving 400 mg ocrelizumab, and 33 were receiving
1,000 mg ocrelizumab, for a total of 64 receiving ocrelizumab. Among patients receiving background MMF, 47 were receiving placebo, 44 were
receiving 400 mg ocrelizumab, and 40 were receiving 1,000 mg ocrelizumab, for a total of 84 receiving ocrelizumab.
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(51% versus 11%). An exploratory ad hoc analysis
showed that patients who received higher baseline IV
glucocorticoid doses had higher overall renal response
rates, particularly placebo-treated patients (38%, 50%,
and 74% for patients receiving glucocorticoid doses of
500 mg, 500 to 1,000 mg, and 1,000 mg, respec-
tively). In addition, a difference in overall renal response
rates between placebo and ocrelizumab was only ob-
served in the 2 subgroups with lower baseline IV gluco-
corticoid doses; overall renal response rates were similar
between placebo and ocrelizumab (74% and 72%, re-
spectively) for patients who received IV glucocorticoid
doses 1,000 mg at baseline (see Supplementary Table
1, available on the Arthritis & Rheumatism web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38037/
abstract). Additional exploratory subgroup analyses of
overall renal response by race and by prior immunosup-
pressant use are presented in Supplementary Table 1.
Serologic end points. Exploratory analyses were
performed on changes from baseline to week 48 in
serum C3, C4, and anti–double-stranded DNA (anti-
dsDNA) levels. In the modified ITT population, ocreli-
zumab significantly increased complement levels and
significantly reduced anti-dsDNA levels at week 48 (P 
0.001), with similar degrees of improvement for both
doses (Table 4). Among patients with abnormal levels at















Percentage of baseline at week 48 in anti-dsDNA,
geometric mean (95% CI)
All patients 54 (43, 67) 30 (24, 37) 32 (26, 39) 31 (27, 36)
Patients receiving background ELNT regimen 64 (42, 96) 34 (23, 48) 33 (23, 48) 33 (26, 43)
Patients receiving background MMF 49 (38, 64) 28 (21, 36) 31 (24, 39) 29 (25, 35)
P† – – – 0.001
Patients with normalized anti-dsDNA levels at
week 48, % (no./total no.)
All patients 14 (8/57) 31 (18/58) 25 (15/60) 28 (33/118)
Patients receiving background ELNT regimen 14 (3/22) 30 (7/23) 35 (9/26) 33 (16/49)
Patients receiving background MMF 14 (5/35) 31 (11/35) 18 (6/34) 25 (17/69)
P‡ – – – 0.044
Change from baseline to week 48 in C3,
mean  SEM mg/dl
All patients 14.5  2.6 24.1  6.3 28.8  3.2 26.4  3.6
Patients receiving background ELNT regimen 9.5 4.2 26.5 6.2 29.7  4.7 28.1  30.5
Patients receiving background MMF 17.5 3.3 22.4  9.9 28.2 4.5 25.1  51.6
P† – – – 0.001
Patients with normalized C3 levels at week 48,
% (no./total no.)
All patients 22 (14/65) 55 (34/62) 63 (36/57) 59 (70/119)
Patients receiving background ELNT regimen 21 (5/24) 52 (13/25) 74 (17/23) 63 (30/48)
Patients receiving background MMF 22 (9/41) 57 (21/37) 56 (19/34) 56 (40/71)
P‡ – – – 0.001
Change from baseline to week 48 in C4,
mean  SEM mg/dl
All patients 1.3  0.8 4.9  0.9 5.2  0.8 5.1 0.6
Patients receiving background ELNT regimen 0.5  1.9 5.4 1.8 5.0  1.1 5.2  1.0
Patients receiving background MMF 2.3 0.6 5.0  1.1 5.4  1.1 5.0  0.7
P† – – – 0.001
Patients with normalized C4 levels at week 48,
% (no./total no.)
All patients 25 (14/56) 54 (26/48) 54 (26/48) 54 (52/96)
Patients receiving background ELNT regimen 20 (4/20) 59 (13/22) 56 (10/18) 58 (23/40)
Patients receiving background MMF 28 (10/36) 50 (13/26) 53 (16/30) 52 (29/56)
P‡ – – – 0.001
* 95% CI  95% confidence interval (see Table 2 for other definitions).
† Versus placebo, by analysis of covariance with adjustment by standard of care and baseline value.
‡ Versus placebo, by Cochran-Mantel-Haenszel test with stratification by standard of care for patients with abnormal levels at baseline.
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baseline, ocrelizumab increased the proportion of pa-
tients with normalized C3, C4, and anti-dsDNA levels
at week 48 (P  0.001, P  0.001, and P  0.044,
respectively) (Table 4). Stratification of patients accord-
ing to serologic status indicated that clinical benefit
(overall renal response at week 48) from ocrelizumab
was greatest among patients with low levels of C3 and C4
at baseline (adjusted treatment difference 21% [95% CI
5, 37]) (see Supplementary Table 1, available on the
Arthritis & Rheumatism web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.38037/abstract). Patients with
normal levels of C3 and C4 showed no increase in
overall renal response at week 48 with ocrelizumab
versus placebo (58% versus 61%, respectively). Simi-
larly, patients with normal anti-dsDNA levels at baseline
did not show an increase in overall renal response at
week 48 with ocrelizumab compared with placebo (50%
versus 44%, respectively).
Pharmacodynamics. Treatment with ocrelizumab
led to rapid depletion of CD19 B cells, with levels re-
maining well below the lower limit of normal (80 cells/l)
through week 48. Patients receiving the ELNT regimen
appeared to show a somewhat greater depletion and
slower repletion compared with patients receiving MMF,
a difference also seen in the placebo-treated group
(see Supplementary Figure 2, available on the Arthritis &
Rheumatism web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38037/abstract).
Safety. Overall, 84.9% of patients reported an
AE during the 48-week, double-blind period (Table 5).
The most common AEs were diarrhea (19.6%), upper
respiratory tract infection (14.3%), urinary tract infec-
tion (11.9%), infusion-related reactions (11.6%), and
nasopharyngitis (10.8%). In general, AEs occurred with
similar frequencies in each treatment group; infusion-
related reactions, however, were more frequent with
ocrelizumab. Infusion-related reactions were more com-
mon with the first infusion of the first course and
diminished with subsequent infusions (Table 5). Two
patients in the ocrelizumab-treated groups reported
serious infusion-related reactions (1 angioneurotic edema,
1 hypertension and ventricular extrasystole); both re-
solved without sequelae.
Overall, 28.3% of patients reported a serious AE
up to week 48. Serious AEs occurred in a greater
proportion of 400 mg ocrelizumab–treated patients than
in placebo-treated or 1,000 mg ocrelizumab–treated
patients (Table 5). Neutropenia as a serious AE was only










Patients with 1 AE, no. (%) 110 (88.0) 109 (86.5) 102 (80.3) 321 (84.9)
Patients receiving background ELNT regimen, no./total no. (%) 36/45 (80.0) 36/47 (76.6) 29/48 (60.4) 101/140 (72.1)
Patients receiving background MMF, no./total no. (%) 74/80 (92.5) 73/79 (92.4) 73/79 (92.4) 220/238 (92.4)
Patients with serious AEs, no. (%) 34 (27.2) 45 (35.7) 28 (22.0) 107 (28.3)
Patients receiving background ELNT regimen, no./total no. (%) 17/45 (37.8) 13/47 (27.7) 9/48 (18.8) 39/140 (27.9)
Patients receiving background MMF, no./total no. (%) 17/80 (21.3) 32/79 (40.5) 19/79 (24.1) 68/238 (28.6)
Patients with infections, no. (%) 70 (56.0) 86 (68.3) 75 (59.1) 231 (61.1)
Patients receiving background ELNT regimen, no./total no. (%) 20/45 (44.4) 29/47 (61.7) 19/48 (39.6) 68/140 (48.6)
Patients receiving background MMF, no./total no. (%) 50/80 (62.5) 57/79 (72.2) 56/79 (70.9) 163/238 (68.5)
Patients with serious infections, no. (%) 18 (14.4) 27 (21.4) 19 (15.0) 64 (16.9)
Patients receiving background ELNT regimen, no./total no. (%) 5/45 (11.1) 5/47 (10.6) 5/48 (10.4) 15/140 (10.7)
Patients receiving background MMF, no./total no. (%) 13/80 (16.3) 22/79 (27.8) 15/79 (19.0) 53/238 (22.3)
Patients with opportunistic infections, no. (%) 1 (0.8) 4 (3.2) 1 (0.8) 6 (1.6)
Patients receiving background ELNT regimen, no./total no. (%)† 0 1/47 (2.1) 0 1/140 (0.7)
Patients receiving background MMF, no./total no. (%)‡ 1/80 (1.3) 3/79 (3.8) 1/79 (1.3) 5/238 (2.1)
Patients with infusion-related reactions, no. (%) 11 (8.8) 15 (11.9) 18 (14.2) 44 (11.6)
Day 1, no. (%) 7 (5.6) 9 (7.1) 15 (11.8) 31 (8.2)
Day 15, no./total no. (%)§ 3/122 (2.5) 6/123 (4.9) 2/124 (1.6) 11/369 (3.0)
Week 16, no./total no. (%)§ 2/95 (2.1) 1/98 (1.0) 2/94 (2.1) 5/287 (1.7)
Week 32, no./total no. (%)§ 0/65 1/67 (1.5) 0/65 1/197 (0.5)
Patients with serious infusion-related reactions, no. (%) 0 1 (0.8) 1 (0.8) 2 (0.5)
* AE  adverse event (see Table 2 for other definitions).
† Includes 1 case of Pneumocystis jiroveci and cytomegalovirus pneumonia.
‡ Includes tuberculosis (placebo), disseminated herpes zoster, systemic herpes, and cryptococcal meningitis (all 400 mg ocrelizumab), and
disseminated herpes/P jiroveci (1,000 mg ocrelizumab).
§ The denominators are the number of patients who received the study drug at the visit.
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reported with ocrelizumab treatment (1.6% of 400 mg
ocrelizumab–treated patients and 2.4% of 1,000 mg
ocrelizumab–treated patients). A total of 231 patients
(61.1%) reported an infection during the study, with
the highest incidence in the group receiving 400 mg
ocrelizumab (Table 5). Infection rates were also highest
with 400 mg ocrelizumab (210.7 events [95% CI 186.1,
238.5] per 100 patient-years, compared with 149.5 events
[95% CI 128.6, 174.0] per 100 patient-years for placebo
and 179.1 events [95% CI 156.3, 205.2] per 100 patient-
years for 1,000 mg ocrelizumab). A higher incidence of
infections occurred in patients from Asia (74.7%) com-
pared with patients from the rest of the world (57.0%).
Serious infections were reported in 16.9% of
patients, the most common being pneumonia, which
occurred with the highest frequency with 1,000 mg
ocrelizumab (5.5%, versus 2.4% and 1.6% with 400 mg
ocrelizumab and placebo, respectively). Cellulitis was
the most frequently reported serious infection with
400 mg ocrelizumab, while gastroenteritis was most
frequently reported in the placebo-treated group. Over-
all serious infection rates per 100 patient-years were 18.7
(95% CI 12.2, 28.7), 28.8 (95% CI 20.6, 40.3), and 25.1
(95% CI 17.4, 36.1) in the placebo-treated, 400 mg
ocrelizumab–treated, and 1,000 mg ocrelizumab–treated
groups, respectively. Overall serious infection rates per
100 patient-years were 43.0 (95% CI 30.7, 60.2) for
patients recruited in Asia and 18.7 (95% CI 14.2, 24.7)
for those recruited outside of Asia. A similar trend
was seen when each treatment group was analyzed
separately.
Six opportunistic infections were reported
(Table 5). All but 1 case occurred in patients receiving
background MMF therapy, and all were reported out-
side the US (3 from Asia, 2 from South America, and
1 from Canada). The single opportunistic infection in
the group receiving the ELNT regimen was a case of
Pneumocystis jiroveci and cytomegalovirus pneumonia
in a patient who received 400 mg ocrelizumab. The 5
opportunistic infections in patients receiving back-
ground MMF therapy were tuberculosis (placebo),
disseminated herpes zoster, systemic herpes, and cryp-
tococcal meningitis (all 400 mg ocrelizumab), and dis-
seminated herpes/P jiroveci (1,000 mg ocrelizumab).
MMF doses received by patients experiencing oppor-
tunistic infections ranged from 20 to 56 mg/kg/day
(before onset of infection). There were 14 deaths during
the study; 6 occurred in the placebo-treated group
(1 case each of acute myeloid leukemia, acute myo-
cardial infarction, cardiac failure, cardiorespiratory ar-
rest, myocardial infarction, and pulmonary embolism).
Three deaths occurred in the 400 mg ocrelizumab–
treated group due to cerebral hemorrhage, disseminated
intravascular coagulation, and acute renal failure. The
5 deaths in the 1,000 mg ocrelizumab–treated group
were caused by pneumonia (n  3), septic shock, and
urosepsis.
Safety was assessed by standard of care regimen.
As shown in Table 5, the general incidence of AEs was
lower among patients receiving the background ELNT
regimen than among those receiving background MMF
(72.1% versus 92.4%). The incidence of infusion-related
reactions was also lower in those receiving the back-
ground ELNT regimen (7.1%, versus 14.3% for those
receiving background MMF). Ocrelizumab-treated pa-
tients receiving the background ELNT regimen also had
a lower incidence of serious AEs than did those receiv-
ing background MMF (Table 5). Overall, the proportion
of patients with infections was lower in those receiving
the background ELNT regimen than in those receiving
background MMF (48.6% versus 68.5%). This was also
the case for serious infections; rates per 100 patient-
years were similar among the treatment groups for
patients receiving the background ELNT regimen (17.5
[95% CI 8.3, 36.6], 18.7 [95% CI 9.3, 37.3], and 19.0
[95% CI 9.5, 38.0] for the placebo-treated, 400 mg
ocrelizumab–treated, and 1,000 mg ocrelizumab–treated
groups, respectively). Patients receiving background
MMF who received ocrelizumab had higher serious
infection rates per 100 patient-years (34.5 [95% CI 23.5,
50.7] and 28.6 [95% CI 18.6, 43.8] for 400 mg ocreli-
zumab and 1,000 mg ocrelizumab, respectively) than
those who received placebo (19.4 [95% CI 11.5, 32.7]).
Most serious infections occurred during the first 12
weeks of treatment for both standard of care therapies
(data not shown), and serious infection rates for all
treatment groups were considerably lower between
weeks 12 and 48.
DISCUSSION
Owing to the early stopping and unblinding of
this study and the inherent difficulty with interpreting
clinical data collected under these circumstances, effi-
cacy results for the primary outcome focused on a subset
of patients who received treatment for a period of at
least 32 weeks. In these patients, overall renal response
rates were similar with both doses of ocrelizumab plus
background standard of care, with an estimated treat-
ment difference of 12.7% versus placebo. The early
stopping of the trial limited the assessment of efficacy to
changes observed at 48 weeks, and therefore any poten-
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tial benefits of ocrelizumab treatment on long-term
renal performance could not be determined.
Addition of ocrelizumab to MMF did not appear
to provide any further benefit in terms of overall renal
response, while addition of ocrelizumab to an ELNT
regimen did lead to some improvement in overall renal
response. An exploratory ad hoc analysis found that
patients with baseline IV glucocorticoid doses 1,000 mg
generally achieved higher overall renal response rates
(and addition of ocrelizumab for this subgroup did not
appear to further increase the overall renal response
rate). As a smaller proportion of placebo-treated pa-
tients receiving a background ELNT regimen received
baseline IV glucocorticoid doses 1,000 mg compared
with placebo-treated patients receiving background
MMF (n  3 [11%] versus n  24 [51%]), this may
provide an explanation for the lower overall renal re-
sponse rates observed with the ELNT regimen. The
placebo-treated patients receiving a background ELNT
regimen had unexpectedly low renal response rates
compared with previous results from the Euro-Lupus
Nephritis Trial (5). Glucocorticoid dosing may explain
this difference, as patients in the Euro-Lupus Nephritis
Trial (5) received a much higher baseline glucocorticoid
dose (3  750 mg pulses of IV methylprednisolone)
compared with the vast majority of patients receiving
a background ELNT regimen in the present study.
Although background glucocorticoid dosing could ex-
plain differences in ocrelizumab efficacy in combination
with the 2 background regimens, the study was not
designed to compare efficacy between the 2 regimens,
and no conclusions about this could be drawn from these
observations.
Similar to results seen in the rituximab LUNAR
trial, ocrelizumab treatment led to increases in comple-
ment levels (C3, C4) and a reduction in anti-dsDNA levels.
Furthermore, in exploratory analyses, the subgroup of
patients with normal complement levels did not show an
increase in overall renal response rates with ocrelizu-
mab. The observed difference in overall renal response
rates between the ocrelizumab- and placebo-treated
groups was restricted to the subgroup of patients with
lower/abnormal serologic parameter levels at baseline.
With regard to safety, the frequency of infusion
reactions was typically highest with the first infusion
and then reduced with successive infusions—a consistent
finding across several diseases treated with anti-CD20
therapies. This difference is presumably due to a larger
B cell number and subsequent cytokine release with the
first infusion.
An increase in the rates of serious AEs and
serious infections was observed with 400 mg ocreli-
zumab, but not with the higher dose. The reason for the
apparent difference in serious infection rates between
the ocrelizumab doses is unclear. In general, serious
infection rates were lower among patients receiving
background CYC/AZA. Indeed, the addition of ocreli-
zumab (either dose) to background CYC/AZA did not
lead to an increase in the rate of serious infections. In
contrast, patients receiving background MMF who re-
ceived ocrelizumab showed an increase in serious infec-
tion rates compared with those who received placebo,
with little difference between the doses.
One potential explanation for the apparently
higher rate of infections in the group who received
background MMF is the dose of baseline IV glucocor-
ticoids; a greater proportion of patients who received
background MMF than patients who received a back-
ground ELNT regimen received a baseline IV glucocor-
ticoid dose1,000 mg. The combination of a different B
cell–targeted treatment, atacicept, with background
MMF was associated with rapid onset of hypogamma-
globulinemia and severe infection in LN patients (27). A
similar interaction between ocrelizumab and MMF in
LN patients with proteinuria may provide an explanation
for the increased rate of serious infections in the current
study. Other differences in ocrelizumab safety were also
observed between the 2 background standard of care
regimens. There was a trend toward a higher rate of
AEs with background MMF compared with the back-
ground ELNT regimen. In particular, patients who re-
ceived MMF tended to report diarrhea more frequently
than did those receiving the background ELNT regimen,
an observation that was not unexpected (28).
The timing of serious infections is also of inter-
est. The majority of serious infections occurred during
the first 12 weeks of the study, irrespective of back-
ground standard of care. One explanation for this ob-
servation is the higher levels of concomitant glucocorti-
coid medication and higher overall disease activity
in patients during the early period of the study. Over-
all, patients who had serious infections during the 48-
week treatment period received a somewhat higher
level of equivalent prednisone doses compared with
patients who did not have serious infections, regardless
of treatment group (mean  SD 19  10 mg/day versus
15  8 mg/day).
Analysis of the rates of infections and serious
infections indicated a clear difference between patients
who were recruited in Asia and those who were not. The
reasons for this difference are currently not known but
are unlikely to involve differences in baseline immuno-
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globulin levels, concomitant mean prednisone doses, or
weight-adjusted MMF doses, which were comparable
between Asian and non-Asian patients in this study
(data not shown). The differences could instead have
been a result of differences in the use of other concom-
itant medications or other patient characteristics, such
as longer LN duration or higher proteinuria among
Asian patients. Another possible factor could be a
higher prevalence of, or susceptibility to, certain infec-
tious diseases in Asia. The lower average body weight of
Asian patients could also have led to higher by-weight
ocrelizumab dosing among these patients. The dose per
weight was not different between Asian and non-Asian
patients receiving 400 mg ocrelizumab (mean dose per
60 kg body weight: 1.4 gm in Asians versus 1.4 gm in
non-Asians) but was higher among Asian patients re-
ceiving 1,000 mg ocrelizumab (3.8 gm versus 3.2 gm).
The higher rates of serious infections seen in Asian
patients who received ocrelizumab are consistent with
results from the ocrelizumab RA clinical trials (24,25).
Higher infection rates among Asian patients were also
observed in the Aspreva Lupus Management Study
trial (9).
Although the incidence of serious opportunistic
infections was low, an apparent imbalance was observed
between the 400 mg ocrelizumab– and placebo-treated
groups (3.2% versus 0.8%, respectively) that was not
seen with 1,000 mg ocrelizumab (0.8%). This increased
frequency of serious opportunistic infections was the
principal reason for study termination.
In conclusion, patients with severe LN who re-
ceived ocrelizumab in combination with standard of care
therapy had a higher incidence of infections (serious or
opportunistic) compared with those receiving placebo
plus standard of care. This study was terminated early by
the sponsor following a reassessment of the benefit/risk
ratio of anti-CD20 therapy in LN. Therefore, definitive
conclusions cannot be drawn regarding the beneficial ef-
fect of adding ocrelizumab to MMF or ELNT CYC
background therapy. Ocrelizumab continues to be inves-
tigated as a potential treatment for multiple sclerosis (29).
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